Cargando…

Recent advances in JAK inhibitors for the treatment of metabolic syndrome

With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around...

Descripción completa

Detalles Bibliográficos
Autores principales: Collotta, Debora, Franchina, Maria Paola, Carlucci, Virginia, Collino, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494544/
https://www.ncbi.nlm.nih.gov/pubmed/37701031
http://dx.doi.org/10.3389/fphar.2023.1245535
_version_ 1785104715737989120
author Collotta, Debora
Franchina, Maria Paola
Carlucci, Virginia
Collino, Massimo
author_facet Collotta, Debora
Franchina, Maria Paola
Carlucci, Virginia
Collino, Massimo
author_sort Collotta, Debora
collection PubMed
description With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around the waist and abnormal cholesterol or triglyceride levels. These conditions lead directly to several disorders, including obesity, dyslipidemia, hyperglycaemia, insulin resistance, impaired glucose tolerance and hypertension causing an increase in cardiovascular risk and in particular atherosclerotic disease. Despite efforts to promote healthier lifestyles through exercise, reduced caloric intake, and improved dietary choices, the incidence and prevalence of metabolic syndrome continue to rise worldwide. Recent research has highlighted the involvement of signaling pathways in chronic inflammatory conditions like obesity and type 2 diabetes mellitus, revealing the significance of the JAK/STAT pathway in atherosclerotic events. This pathway serves as a rapid membrane-to-nucleus signaling module that regulates the expression of critical mediators. Consequently, JAK inhibitors (JAKi) have emerged as potential therapeutic options for metabolic diseases, offering a promising avenue for intervention. The aim of this review is to shed light on the emerging indications of JAK inhibitors in metabolic syndrome, emphasizing their potential role in attenuating associated inflammatory processes, improving insulin sensitivity, and addressing cross-talk with the insulin pathway, with the intention of contributing to efforts in the field of inflammation pharmacology.
format Online
Article
Text
id pubmed-10494544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104945442023-09-12 Recent advances in JAK inhibitors for the treatment of metabolic syndrome Collotta, Debora Franchina, Maria Paola Carlucci, Virginia Collino, Massimo Front Pharmacol Pharmacology With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around the waist and abnormal cholesterol or triglyceride levels. These conditions lead directly to several disorders, including obesity, dyslipidemia, hyperglycaemia, insulin resistance, impaired glucose tolerance and hypertension causing an increase in cardiovascular risk and in particular atherosclerotic disease. Despite efforts to promote healthier lifestyles through exercise, reduced caloric intake, and improved dietary choices, the incidence and prevalence of metabolic syndrome continue to rise worldwide. Recent research has highlighted the involvement of signaling pathways in chronic inflammatory conditions like obesity and type 2 diabetes mellitus, revealing the significance of the JAK/STAT pathway in atherosclerotic events. This pathway serves as a rapid membrane-to-nucleus signaling module that regulates the expression of critical mediators. Consequently, JAK inhibitors (JAKi) have emerged as potential therapeutic options for metabolic diseases, offering a promising avenue for intervention. The aim of this review is to shed light on the emerging indications of JAK inhibitors in metabolic syndrome, emphasizing their potential role in attenuating associated inflammatory processes, improving insulin sensitivity, and addressing cross-talk with the insulin pathway, with the intention of contributing to efforts in the field of inflammation pharmacology. Frontiers Media S.A. 2023-08-24 /pmc/articles/PMC10494544/ /pubmed/37701031 http://dx.doi.org/10.3389/fphar.2023.1245535 Text en Copyright © 2023 Collotta, Franchina, Carlucci and Collino. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Collotta, Debora
Franchina, Maria Paola
Carlucci, Virginia
Collino, Massimo
Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title_full Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title_fullStr Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title_full_unstemmed Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title_short Recent advances in JAK inhibitors for the treatment of metabolic syndrome
title_sort recent advances in jak inhibitors for the treatment of metabolic syndrome
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494544/
https://www.ncbi.nlm.nih.gov/pubmed/37701031
http://dx.doi.org/10.3389/fphar.2023.1245535
work_keys_str_mv AT collottadebora recentadvancesinjakinhibitorsforthetreatmentofmetabolicsyndrome
AT franchinamariapaola recentadvancesinjakinhibitorsforthetreatmentofmetabolicsyndrome
AT carluccivirginia recentadvancesinjakinhibitorsforthetreatmentofmetabolicsyndrome
AT collinomassimo recentadvancesinjakinhibitorsforthetreatmentofmetabolicsyndrome